Triple Therapy For Patients With Mutated FLT3 Gene In Acute Myeloid Leukemia Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Innhold levert av Oncology Times. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncology Times eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Oncology Times - OncTimes Talk « »
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

3M ago 20:15

Del

Innhold levert av Oncology Times. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncology Times eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy.

The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are present in nearly a third of all AML tumors. The internal tandem duplication mutation of FLT3, in particular, is associated with poor prognosis in AML. So, it was hypothesized that targeting FLT3 could help in treating FLT3-mutated AML.

First author Musa Yilmaz MD, Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, has been talking with OncTimesTalk correspondent Peter Goodwin.

… continue reading

152 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

Oncology Times - OncTimes Talk

21 subscribers

published 3M ago

Del

Innhold levert av Oncology Times. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncology Times eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy.

The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are present in nearly a third of all AML tumors. The internal tandem duplication mutation of FLT3, in particular, is associated with poor prognosis in AML. So, it was hypothesized that targeting FLT3 could help in treating FLT3-mutated AML.

First author Musa Yilmaz MD, Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, has been talking with OncTimesTalk correspondent Peter Goodwin.

… continue reading

152 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Все серии

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema